Publication | Open Access

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma

Hematological MalignancyMedicinal ChemistryHigh Kinome SelectivityBioavailable Cdk 4/6MedicineMalignant Blood DisorderMultiple MyelomaPharmacotherapyAnti-cancer AgentPharmacologyRadiation OncologyNovel TherapyDrug DiscoveryMyeloid Neoplasia